REGULATED INFORMATIONREGULATED INFORMATIONREGULATED INFORMATION
HALF YEAR REPORT ON THE LIQUIDITY CONTRACT Paris and Boston, July 27, 2017 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.The liquidity account had the following holdings as of June 30, 2017:
- 131,934 shares
- € 390,277.09
For the prior (December 31, 2016), the corresponding figures were:
- 394 422 shares
- 134 790,14€
About NeovacsListed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson+33 (0)1 53 10 93 14
cmasson@neovacs.com
LIFESCI ADVISORS- Investor Relations / Financial Communications Chris Maggos+41 79 367 6254
chris@lifesciadvisors.com
Neovacs SA published this content on 27 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 July 2017 09:14:03 UTC.
Original documenthttp://neovacs.fr/wp-content/uploads/2017/07/neovacs_regulated-information_liquidity-contract-juin-2017.pdf
Public permalinkhttp://www.publicnow.com/view/A69953EF1B47A3EB8DB0B5D318334BC8018D3A75